Alembic Pharmaceuticals Limited announced its unaudited financial results for the quarter and nine months ended 31st December, 2025, showcasing steady growth across key financial metrics. The pharmaceutical company's Board of Directors approved the results at a meeting held on 5th February, 2026, along with a significant board appointment.

Financial Performance Overview

The company delivered robust performance in Q3FY26 with consolidated revenue from operations reaching Rs 1,876.31 crore, marking a 10.8% year-on-year growth from Rs 1,692.74 crore in Q3FY25. However, this represented a slight sequential decline from Rs 1,910.15 crore in Q2FY26.

Nine-Month Performance

For the nine-month period ended 31st December, 2025, the company demonstrated strong momentum with consolidated revenue of Rs 5,497.18 crore, representing a 12.1% increase from Rs 4,902.45 crore in the corresponding period of the previous year. Net profit for the nine-month period stood at Rs 472.07 crore compared to Rs 426.53 crore in the same period last year, reflecting a 10.7% growth.

Exceptional Items Impact

The company's Q3FY26 results were affected by an exceptional item of Rs 42.23 crore related to the implementation of new Labour Codes. On 21 November 2025, the Government of India notified provisions of Labour Codes that consolidate twenty-nine existing labour laws. This resulted in an incremental impact relating to gratuity and long-term compensated absences arising from the revised definition of wages.

Board Appointment

Based on the recommendation of the Nomination and Remuneration Committee, the Board appointed Mr. Rajkumar Baheti (DIN: 00332079) as Non-Executive Non-Independent Director, liable to retire by rotation. His appointment will be effective from 1st April, 2026, upon completing his tenure as Executive Director on 31st March, 2026, subject to shareholder approval through postal ballot.

Mr. Baheti is a Commerce graduate and fellow member of both the Institute of Chartered Accountants of India and the Institute of Company Secretaries of India, bringing extensive professional experience in finance and regulatory matters.

Financial Health Indicators

The company maintained healthy financial ratios with a debt-equity ratio of 0.25 times and current ratio of 1.68 times as of 31st December, 2025. The net worth stood at Rs 5,463.32 crore, reflecting the company's strong financial position. Operating margin improved to 16.42% in Q3FY26 from 16.00% in the corresponding quarter of the previous year, while net profit margin was 7.09% compared to 8.18% in Q3FY25.

Alembic Pharmaceuticals Limited has informed stock exchanges about the superannuation of Mr. Ashok Pandya, who served as Resident Director. The pharmaceutical company filed the mandatory disclosure on January 31st, 2026, notifying both BSE and NSE about this senior management change.

Management Transition Details

The company submitted the intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates disclosure of material events and information. The notification was signed by Company Secretary Manisha Saraf and includes detailed annexures as required by regulatory guidelines.

Superannuation Specifics

According to the regulatory filing, the management change occurred due to superannuation, with specific timing and procedural details outlined in the company's disclosure.

Regulatory Compliance

The disclosure demonstrates Alembic Pharmaceuticals' adherence to corporate governance requirements and transparency standards. The company provided comprehensive documentation including annexures as mandated by SEBI regulations for senior management personnel changes.

The notification was addressed to both major Indian stock exchanges where the company's shares are listed, ensuring complete regulatory compliance and stakeholder transparency regarding this organizational transition.